Nail Your Sales Interview with the 30/60/90 Day Sales Plan
If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.

Now you can nail your interview with the 30 60 90 Day Sales Plan template with Audio Coaching. This simple tool will help you knock the socks off your interviewer and bury your competition.

To get the details: Click Here

[Close Window]
Medical Sales Jobs Websites - the best Medical Sales Jobs | Laboratory Sales Jobs | Medical Device Sales Jobs

Posts on ‘December 31st, 2008’

First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform

New Color-Coded Embolic with Polyzene(R)-F Coating Enhances Procedural Safety, Efficiency during Treatment of Hypervascularized Tumors and Arteriovenous Malformations NEWNAN, Ga., Dec. 31 (HSMN NewsFeed) — Against the backdrop of a flagging economy, …
Devices, Interventional, Oncology
CeloNova BioSciences, Embozene, microspheres, embolization

Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million

SAN CARLOS, Calif., Dec. 31 (HSMN NewsFeed) — Nektar Therapeutics (Nasdaq: NKTR ) today announced that it has successfully closed the divestiture of specific Nektar pulmonary delivery assets, technology, and intellectual property to Novartis for $115 mi…
Biopharmaceuticals, Drug Delivery, Acquisitions
Nektar Therapeutics, Novartis, Tobramycin

China Medical Technologies Announces the Completion of the Sale of its HIFU Business

BEIJING, Dec. 31 (HSMN NewsFeed) — China Pathology Technologies, Inc. (the "Company") (Nasdaq: CMED ), a big China-based pharmaceutical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that…
Devices, Acquisitions
China Clinical Technologies, Chengxuan, HIFU

FDA Cardio Renal Advisory Committee to Review Daiichi Sankyo, Lilly Drug Prasugrel

TOKYO and INDIANAPOLIS, Dec. 31 (HSMN NewsFeed) — Daiichi Sankyo Company, Limited (TSE: 4568 ) and Eli Lilly and Company (NYSE: LLY ) today confirmed that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (C…
Biopharmaceuticals, Cardiology
Eli Lilly, Daiichi Sankyo, Prasugrel, acute coronary syndrome

PriCara(R) Recalls 50 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches

Other Strength Patches (12.5, 25, Seventy five and 100 mcg/hr) Not Affected RARITAN, N.J., Dec. 31 (HSMN NewsFeed) — PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., said today that one lot of 50 microgram/hour (mcg/hr) DURAGESIC® (fen…
Biopharmaceuticals, Drug Delivery, Product Recall
PriCara, Ortho-McNeil-Janssen Pharmaceuticals, DURAGESIC, fentanyl transdermal

Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain

Product to be Launched in the U.S. in the Second Quarter of 2009 LAVAL, QC, Dec. 31 (HSMN NewsFeed) - Labopharm Inc. (TSX: DDS ; NASDAQ: DDSS ) today announced that RYZOLT(TM) (tramadol HCl extended release tablets), Labopharm’s once-daily formulation…
Biopharmaceuticals, FDA
Labopharm, tramadol, RYZOLT